Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir-Reference-Cited by-同舟云学术

Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir

Published:2013-09-02 Issue:4 Volume:21 Page:260-263
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Boglione L.¹,De Nicolò A.¹,Cusato J.¹,Cariti G.¹,Di Perri G.¹,D'Avolio A.¹

Affiliation:

1. Unit of Infectious Diseases, University of Turin, Department of Medical Sciences; Amedeo di Savoia Hospital; Turin Italy

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12170/fullpdf

Reference8 articles.

1. Telaprevir for previously untreated chronic hepatitis C virus infection;Jacobson;N Engl J Med,2011

2. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage;Franceschi;Hepatology,2000

3. P_21 Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population;Nicolò;Rev Antiv Ther Infect dis,2013

4. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment;D'Avolio;Ther Drug Monit,2012

5. PP_02 Increased plasma and intracellular ribavirin concentrations associated with telaprevir use;Hammond;Rev Antiv Ther Infect dis,2013

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens;PLOS ONE;2018-05-31

2. Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study;Journal of Antimicrobial Chemotherapy;2018-03-02

3. Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals;Alimentary Pharmacology & Therapeutics;2017-09-07

4. Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations;Digestive and Liver Disease;2017-06

5. Pharmacogenetics of ribavirin-induced anemia in HCV patients;Pharmacogenomics;2016-06